Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

Table 1

Patient and tumor characteristics by group.

	TKI treated		Naive
	Number	%	Number	%
Total	19	100	73	100
Gender
Male	19	100	60	82.2
Female			13	17.8
Age (years)
Median	66		60
Range	38–75		36–82
Histological type
SCC	18	94.7	69	94.5
Other	1	5.3	2	2.7
Unknown			2	2.7
Smoking status
Yes	18	94.7	64	87.7
No			8	11.0
Unknown	1	5.3	1	1.3
Alcohol
Yes	11	57.9	56	76.7
No	7	36.8	15	20.5
Unknown	1	5.3	2	2.7